​

Funding Round

Series B - ProfoundBio

Series B - ProfoundBio

Investment Firm

Overview

ProfoundBio is a developer of targeted therapeutics intended for patients with cancer.

Announced Date

Feb 13, 2024

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

Ally Bridge Group

Ally Bridge Group

Ally Bridge Group is a early_stage_venture and late_stage_venture and post_ipo and private_equity and venture firm.

Participant Investors

10

Investor Name
Participant InvestorOrbiMed
Participant InvestorLYFE Capital
Participant InvestorMedicxi
Participant InvestorT. Rowe Price
Participant InvestorLilly Asia Ventures

Round Details and Background

ProfoundBio raised $112000000 on 2024-02-13 in Series B

ProfoundBio is a developer of targeted therapeutics intended for patients with cancer.

Company Funding History

4

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jul 12, 2021
Series A - ProfoundBio
7-55.0M
Feb 08, 2021
Seed Round - ProfoundBio
2-10.0M
Jun 02, 2022
Series A - ProfoundBio
6-70.0M
Feb 13, 2024
Series B - ProfoundBio
14-112.0M

Recent Activity

There is no recent news or activity for this profile.